Parallel Advisors, LLC Akero Therapeutics, Inc. Transaction History
Parallel Advisors, LLC
- $4.31 Billion
- Q1 2025
A detailed history of Parallel Advisors, LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 5,169 shares of AKRO stock, worth $267,599. This represents 0.01% of its overall portfolio holdings.
Number of Shares
5,169
Previous 5,539
6.68%
Holding current value
$267,599
Previous $154,000
42.86%
% of portfolio
0.01%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding AKRO
# of Institutions
270Shares Held
86MCall Options Held
1.02MPut Options Held
823K-
Rtw Investments, LP New York, NY7.42MShares$384 Million4.92% of portfolio
-
Janus Henderson Group PLC London, X07.07MShares$366 Million0.16% of portfolio
-
Wellington Management Group LLP Boston, MA5.94MShares$307 Million0.05% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$289 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$271 Million7.15% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.4B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...